Related Experiment Video

Updated: May 24, 2026

Isolation and Differentiation of Stromal Vascular Cells to Beige/Brite Cells
07:22

Isolation and Differentiation of Stromal Vascular Cells to Beige/Brite Cells

Published on: March 28, 2013

Peroxisome proliferator-activated receptor (PPAR α/γ) agonists as a potential target to reduce cardiovascular risk in

Stephen J Nicholls1, Kiyoko Uno

  • 1Cleveland Clinic Coordinating Center for Clinical Research and Department of Cardiovascular Medicine, Cleveland Clinic, OH 44195, USA. nichols1@ccf.org

Diabetes & Vascular Disease Research
|March 13, 2012
PubMed

Insights

New therapies are needed to lower cardiovascular risk in type 2 diabetes. This review examines dual peroxisome proliferator-activated receptor-alpha/gamma (PPAR-α/γ) agonists as a potential strategy, considering past study outcomes.

Area of Science:

  • Diabetes Mellitus Research
  • Cardiovascular Risk Reduction
  • Pharmacological Interventions

Background:

  • Type 2 diabetes management requires novel strategies beyond glucose lowering to address significant cardiovascular risks.
  • Metabolic abnormalities in diabetes offer multiple targets for therapeutic development.
  • Peroxisome proliferator-activated receptors (PPARs) are a potential target, but previous studies with agonists yielded varied results.

Purpose of the Study:

  • To review findings from previous studies on PPAR modulation.
  • To present the rationale for developing dual PPAR-α/γ agonists.
  • To discuss their potential in reducing cardiovascular risk in type 2 diabetes.

Main Methods:

  • Review of existing literature on PPAR agonists in type 2 diabetes.
  • Analysis of outcomes from glucose-lowering and cardiovascular risk studies.
  • Examination of the mechanistic basis for dual PPAR-α/γ agonism.

Main Results:

  • Previous PPAR agonist studies showed inconsistent effects on cardiovascular outcomes.
  • Dual PPAR-α/γ agonists offer a potentially more effective approach by targeting multiple metabolic pathways.
  • Understanding these varied results is crucial for future drug development.

Conclusions:

  • Dual PPAR-α/γ agonists represent a promising therapeutic avenue for managing type 2 diabetes and its associated cardiovascular risks.
  • Further research and clinical trials are warranted to validate their efficacy and safety.
  • Targeting PPARs offers a multifaceted approach to metabolic and cardiovascular health in diabetic patients.

More Related Videos

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway07:15

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway

Published on: August 23, 2024

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include: